[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-leukemia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,75,95,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100488853","living-with-chronic-cancer-treatments-longeviti-study-100488853",false,"NCT05645510","LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study","LONGEVITI","Inclusion Criteria: taking chronic targeted anti-cancer agents -\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","90 Years",{"count":20,"type":21},75,"ESTIMATED","OBSERVATIONAL","People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.",[25,26,27,28,29,30,31,32,33,34],"Cancer","Tyrosine Kinase Mutation","Breast Cancer","Melanoma","Multiple Myeloma","Chronic Leukemia","Prostate Cancer","Ovarian Cancer","Colorectal Cancer","Lung Cancer","RECRUITING","2026-05-06",{"date":38,"type":39},"2026-05-11","ACTUAL",{"date":41,"type":39},"2022-11-24",{"date":43,"type":21},"2026-06-09",{"name":45,"class":46},"University of Alberta","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100627234","chemogenomic-profiling-in-hematological-malignancies-hem-profiling-2021-100627234","NCT07445984","Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)","Inclusion Criteria:\n\n* Patient aged \\>1 year old, referred for evaluation to the University Hospital of Parma;\n* Retrospective study: previously patients with hematological malignancies;\n* Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate\u002Fbiopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed\u002Frefractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate\u002Fbiopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed\u002Frefractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate\u002Fbiopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc;\n* Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit.\n\nExclusion Criteria:\n\n* Age \\\u003C1 year old\n* Patients who are unable to provide informed consent prior to any procedure for any reason.","1 Year",{"count":56,"type":21},250,"INTERVENTIONAL",[59],"NA","The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.",[30,62,63,64,65],"Acute Leukemia","Myeloproliferative Disorders","Lymphoproliferative Disorders","Myelodysplastic Disorders","2026-02-25",{"date":68,"type":39},"2026-03-03",{"date":70,"type":39},"2021-07-28",{"date":72,"type":21},"2026-07-28",{"name":74,"class":46},"Azienda Ospedaliero-Universitaria di Parma",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100627192","feasibility-of-a-multi-omics-platform-for-hematological-malignancies-100627192","NCT07445438","Feasibility of a Multi-omics Platform for Hematological Malignancies","FOCUS","Inclusion Criteria:\n\n* Patient aged \\> 2 year old\n* Retrospective study:\n* Patients previously diagnosed with hematological malignancies\n* Prospective study:\n* Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nodes or tissues with metastatic involvement, or other biological fluids (such as CSF, pathologic pleural effusion).\n* Patients with clinical suspicion of R\u002FR onco-hematological disorder, requiring a diagnostic assessment using BM aspirate\u002Fbiopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from lumbar puncture, tissue aspirate etc.\n* Patients with blastic transformation from a chronic condition or suspect of R\u002FR hematological disease requiring a diagnostic assessment using PB drawn, BM aspirate\u002Fbiopsy, lymph nodes biopsies, or biopsies of tissues with metastatic involvement, including CSF from lumbar puncture, tissue aspirate, etc.\n\nExclusion Criteria:\n\n* Age \\\u003C2 year old\n* Patient without a diagnosis of hematological malignancy.","2 Years",{"count":84,"type":21},1040,[59],"This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.",[88,30,62,63,64,65],"Myeloma Multiple",{"date":68,"type":39},{"date":91,"type":39},"2025-03-31",{"date":93,"type":21},"2030-03",{"name":74,"class":46},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":57,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100623976","integrative-multi-omics-and-functional-platform-for-the-complete-diagnostic-characterization-of-tumors-the-italian-tumor-chemogenomic-profiler-it-tcp-100623976","NCT07403630","INTEGRATIVE \"MULTI-OMICS\" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)","IT-TCP POS","Inclusion criteria:\n\n* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo).\n* Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group.\n* Patients diagnosed with relapsed, refractory and\u002For metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation.\n* Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent\u002Flegal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent\u002Flegal guardian according to the mature minor principle.\n\nExclusion criteria:\n\n* Patients younger than 1 year old\n* Patients with active, uncontrolled infections",{"count":103,"type":21},300,[59],"This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.",[62,29,107,108,109,110,32,28,111,30,63,65],"Squamous Cell Carcinoma","Pleural Mesothelioma","Pancreatic Cancer","Bladder Cancer","Pediatric Acute Lymphoblastic Leukemia","2026-02-13",{"date":114,"type":39},"2026-02-17",{"date":116,"type":39},"2023-05-31",{"date":118,"type":21},"2028-02-12",{"name":74,"class":46},2,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":47},"100287065","umbilical-cord-blood-transplantation-from-unrelated-donors-100287065","NCT03016806","Umbilical Cord Blood Transplantation From Unrelated Donors","Inclusion Criteria:\n\n* Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited to:\n* Congenital and Other Non-malignant Disorders:\n* Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)\n* Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)\n* Metabolic disorders (e.g. Hurler's Syndrome)\n* Severe aplastic anemia\n* High-Risk Leukemia:\n* Acute Myelogenous Leukemia\n* Refractory to standard induction therapy (more than 1 cycle required to achieve remission)\n\n  * Recurrent (in CR ≥ 2)\n  * Treatment-related AML or MDS\n  * Evolved from myelodysplastic syndrome\n  * Presence of FLT3 abnormalities\n  * FAB M6 or M7\n  * Adverse cytogenetics\n  * Myelodysplastic Syndrome\n  * Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:\n  * Refractory to standard induction therapy (time to CR \\>4 weeks)\n  * Recurrent (in CR ≥ 2)\n  * WBC count \\>30,000\u002FmcL at diagnosis\n  * Age \\>30 at diagnosis\n* Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.\n* Chronic Myelogenous Leukemia in accelerated phase or blast crisis\n* Biphenotypic or undifferentiated leukemia\n* Burkitt's leukemia or lymphoma\n* Lymphoma:\n* Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT\n* Marginal zone or follicular lymphoma that is progressive after at least two prior therapies\n* Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT\n* Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status\n* Adequate organ function:\n* Cardiac - LVEF \\>45%, or shortening fraction \\>25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death\n* Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted;\n* Renal - serum Cr \\\u003C 1.5 times the upper limit of normal for age or GFR ≥ 50 ml\u002Fmin\u002F1.73m2\n* Hepatic - total bilirubin level \\\u003C 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase ≤ 5 times upper limit of normal.\n* Performance Status Karnofsky or Lansky score ≥ 70%.\n* Informed Consent must be obtained prior to initiating conditioning therapy.\n* Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.\n\nExclusion Criteria:\n\n* Availability of 10\u002F10 or 9\u002F10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant\n* Autologous HSCT \\\u003C 6 months prior to proposed UCB transplant\n* Pregnant or breast feeding\n* Current uncontrolled infection\n* Evidence of HIV infection or positive HIV serology","2 Months","75 Years",{"count":130,"type":21},30,"This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).",[62,133,134,135,136,137,30,138,29,139],"Immune Deficiency Disorder","Congenital Hematological Disorder","Metabolism Disorder","Aplastic Anemia","Myelodysplastic Syndromes","Lymphoma","Solid Tumor","2025-10-08",{"date":142,"type":39},"2025-10-10",{"date":144,"type":4},"2015-06",{"date":146,"type":21},"2027-06",{"name":148,"class":46},"University of Rochester"]